Single-agent thalidomide induces response in T-cell lymphoma

European Journal of Haematology

Volumn 74, Issue 2, 2005, Pages 169-171

  Damaj, G ^a,b   Bouabdallah, R ^a   Vey, N ^a   Bilger, K ^a   Mohty, M ^a   Gastaut, J A ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Lymphoma; Thalidomide

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; THALIDOMIDE; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE REPORT; DRUG EFFICACY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOMODULATION; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; T CELL LYMPHOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; THALIDOMIDE;

EID: 12944266926     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00362.x     Document Type: Article

References (24)

1. GISSELBRECHT C, GAULARD P, LEPAGE E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998;92:76-82.
2. SINGHAL S, MEHTA J, DESIKAN R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
3. RAZA A, MEYER P, DUTT D et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-965.
4. TEFFERI A. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new. Semin Hematol 2003;40(Suppl. 1):18-21.
5. GIOVANNI B, MICHELLE E, LETIZIA C et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002;43:2301-2307.
6. STEINS MB, PADRO T, BIEKER R et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002;99:834-839.
7. DIMOPOULOS MA, ZOMAS A, VINIOU NA et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 2001;19:3596-3601.
8. DAMAJ G, LEFRERE F, DELARUE R et al. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 2003;17:1914-1915.
9. WILSON EA, JOBANPUTRA S, JACKSON R et al. Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. Br J Haematol 2002;119:128-130.
10. KAUFMANN H, RADERER M, WOHRER S et al. anti-tumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269-2271.
11. YAKOUB-AGHA I, MOREAU P, LEYFRAZ S et al. Thalidomide in patients with advanced multiple myeloma. Hematol J 2000;1:186-189.
12. JULIUSSON G, CELSING F, TURESSON I et al. Frequent good partial remissions from thalidomide including best response even in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
13. WAAGE A, GIMSING P, JULIUSSON G et al. Early response predicts thalidomide efficiency in patients with multiple myeloma. Br J Haematol 2004;125:149-155.
14. RAJE N, ANDERSON K. Thalidomide - a revival story. N Engl J Med 1999;341:1606-1609.
15. D'AMATO RJ, LOUGHNAN MS, FLYNN E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
16. ROSINOL L, CIBIERA MT, SEGARRA M et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 2004;26:145-148.
17. DAVIES FE, RAJE N, HIDESHIMA T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
18. MOHTY M, STOPPA AM, BLAISE D et al. Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J Leukoc Biol 2002;72:939-945.
19. SETTLES B, STEVENSON A, WILSON K et al. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vivo treatment with the anti-TNF-alpha thalidomide. Cell mol Biol 2001;47:1105-1114.
20. HASLETT PA, KLAUSNER JD, MAKONKAWKEYOON S et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999;15:1169-1179.
21. CORRAL LG, HASLETT PA, MULLER GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-386.
22. KEIFER JA, GUTTRIDGE DC. ASHBURNER BP et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276:22382-22387.
23. LELEU X, MAGRO L, FAWAZ A et al. Efficacy of low dose of thalidomide in advanced multiple myeloma. Blood 2002;100:1519.
24. PALUMBO A, GIACCONE L, BERTOLA A et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Hematologica 2001;86:399-403.